Hyperlipidemia Tx Flashcards

1
Q

Mechanism of HDL return to the liver?

A

HDL returns cholesterol to the liver by one of two ways: 1. HDL is delivered directly to the liver through interaction with the scavenger receptor, class B, type I (SR-BI). 2. cholesteryl esters in HDL are transferred by the cholesteryl ester transfer protein (CETP) to very-low-density lipoproteins (VLDL) and low-density lipoproteins (LDL) and are then returned to the liver through the LDL receptor.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What makes LDL “bad” cholesterol?

What disease increase negative effects of LDL?

A

Plasma lipoproteins that contain Apo B100 including LDL, VLDL, IDL have been identified as vehicles that (1)transport cholesterol to the artery wall. Once at the artery wall, it is thought that (2)oxidation of the lipoproteins creates ligands for the scavenger receptors SR-A or CD36 present on macrophages resulting in the formation of foam cells. These (3)macrophages adhere to vessel walls and migrate underneath the endothelial cells continually endocytose the oxidized lipoproteins forming the atherosclerotic plaque.

Glycation of lipoproteins in poorly controlled diabetes also contributes to foam cell formation. Arterial hypertension also accelerates atherogenesis.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What makes HDL “good”?

A
  1. HDL cholesterol can be taken directly back to the liver, thus it is removing cholesterol from the plasma.
  2. In addition, HDL also decreases atherosclerosis by protecting LDL from oxidation. If LDL is not oxidized it is not readily taken up by the macrophage scavenger receptors.
  3. HDL may also slow the progression of lesions by selectively decreasing the production of endothelial cell-adhesion molecules that facilitate the uptake of inflammatory cells into the vessel wall.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

How is cholesterol regulated?

A

The mechanisms of cholesterol regulation are poorly understood. The liver has a central role in the production and regulation of serum cholesterol. When the liver or extrahepatic tissues require extra cholesterol for synthesis of new membranes, bile acids, or hormones, the liver can increase the synthesis of either cholesterol itself or increase the number of LDL receptors, thereby capturing LDL from the plasma.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Bile Resins

List Drugs in Category

Pharmokinetics

MOA

Adverse Effects

A

Drugs- Cholestyramine and colestipol and colesevelam (FA)

Pharmacokinetics

  • Anion exchange resins that bind negatively charged bile acids in the small intestines Insoluble in water
  • Complex is excreted in the feces

MOA

  • Loss of bile acids leads to compensatory increase in the number of hepatic LDL receptors reduce plasma cholesterol 15-30% decrease in LDL, HMG CoA reductase activity is increased reduces cholesterol loss
  • Triglyceride synthesis is enhanced temporarily then no effect on TG (this is counter intuitive– used in patients with well controlled TAGs but high LDL)

HDL Adverse effects:

  • Increase in Plasma TG levels first few weeks
  • Bad taste (texture- like drinking sand) inconvenient to swallow
  • GI irriation- Abdominal bloating Constipation/ steatorrhea, anal leakage, anal fissures
  • Impairment of other drug absorption: take 1 to 2 hrs before or 3 hr after resin Fat soluble vitamin absorption
  • Poor compliance due to inconvenience and abdominal bloating and steatorrhea
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Ezetimibe

Pharmokinetics

MOA

Adverse Effects

Effects on long term imporvement of mortality?

Alternative to what LLD? Why?

A

Zetia (Ezetimibe)

Pharmacokinetics a.

  • Ezetimibe is absorbed and conjugated to glucuronide in the liver and small intestine. Both Ezetimibe and ezetimibe-glucurinide are pharmacologically active with plasma levels containing 80- 90% of the conjugated form. B
  • oth Ezetimibe and ezetimibe-glucurinide are highly bound to plasma proteins,
  • T1/2= 22 hrs b. Eliminated by liver and kidneys

MOA

  • Ezetimibe is thought to act as a transport inhibitor, blocking the absorption of cholesterol by the brush border cells of the intestine.
  • LDL 18% TG 8% HDL 1% Uses Used to reduce LDL.
  • Unlike the statins, there are no long-term studies demonstrating the effect of ezetimibe on reducing plaque, coronary events or improving mortality. Statins remain the preferred treatment
  • Effects on LDL are additive when used with statin drugs. (see drug combinations)
  • No myopathy effects- a possible alternative to for those that can’t tolerate statins.

Adverse effects

  • Not recommended for patients with moderate or severe hepatic insufficiency.
  • Drug interaction with cyclosporine
  • Appears safe to use in combination with statin drugs, but may cause an elevation of transanimase liver enzymes when used with statins
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Statins

Pharmokinetics

MOA (2)

Adverse Effects

CI?

A

Statins- pravastatin, simvastain, atrovastatin, rosuvastatin

PK

  • Some are pro drugs (lovastatin and simvastatin) others are active or have an additional active metabolite (atorvastatin)
  • T 1/2 varies generally 1-3 hrs, atorvastatin = 14 hrs
  • Excretion predominantly via liver.

MOA

  • The statin drugs inhibit the enzyme HMG CoA reductase. This enzyme catalyzes the conversion of Acetyl CoA to melvonic acid a key step in the synthesis of cholesterol. There is some up-regulation of HMG CoA reductase levels but not enough to reduce the effect on cholesterol synthesis Because of low hepatic cholesterol, the liver increases LDL receptors resulting in decreases serum LDL May also be anti inflammatory (reduce c reactive protein)
  • Most potent and preferred for reduction in LDL
  • 18%-55% HDL 5%-15%  TG 7%-30% Reduction in LDL is dose dependent

Adverse effects: Generally safe and well tolerated, side effects increase with dosage.

  • Check liver enzymes before starting treatment and immediately after starting treatment can cause heptatoxicity (increase LFT)
  • Myopathy may be life threatening Rhabdomyolysis
  • Transanimase hepatitis

Contraindications:

  • Renal Failure
  • Cyclosporine
  • macrolide antibiotics
  • various antifungal agents, and cytochrome P-450 inhibitors
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Which statins have the bet evidence for preventing Heart attack and stroke?

A

simvastatin (Zocor), atorvastatin (Lipitor), and Rosuvastatin (Crestor).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What cholesterol is the best determinant of heart attack?

A

HDL- inverse coorelation!

LDL marginal risk factor

Total Nor predicitive

According to 1977 framington heart study

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Niacin- Other names?

Pharmokinetics

MOA (2)

What is the most effective agent for?

Adverse Effects

CI?

A

Nicotinic acid (Niacin b3)

Pharmacokinetics

  • Much higher dosage, 1-3g, is used for hypolipidemic effect. Vitamin dose is only 20 mg. Niacin is rapidly absorbed and eliminated by renal clearance. Note: The acid form of the drug, Niacin or nicotinic acid, is active. The basic form of the drug, niacinamide or nicotinamide does not have hypolipidemic action.

MOA

  • Inhibition of VLDL secretion LDL 5-25%
  • clearance of VLDL via lipoprotein lipase pathway leads to triglycerides 20-50%
  • Enhanced HDL levels

Uses: Most effective agent for HDL 15%-35%– think of the healthy (HDL) effect of vitamins

Adverse Effects -Just because it is over the counter do not assume that it is safe at these dosages

  • Intense Flushing, and associated Pruritis– One aspirin can relieve the symptoms
  • Nausea, abdominal pain o dosage,+ antacid (not Al3+), AL3+ antacids are contraindicated -peptic ulcer
  • Hyperuricemia
  • Hyperglycemia may decrease glucose tolerance in patients with sub clinical diabetes –Acanthosis nigricans (patches of dark skin) associated with insulin resistance-discontinue
  • Hepatotoxicity transaminase, & ALT, flu-like fatigue
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Firbic acid derivatives- list drugs in this group?

Pharmokinetics

MOA (2)

Most effect at effecting which type of choleterol?

Adverse Effects

A

Fibric acid derivative- Gemfibrozil, clofibrate, bezofibrate, fenofibrate

Pharmacokinetics

  • Well absorbed 95% protein bound may displace warfarin 60-90%
  • excreted in urine

MOA

  • Upregulated LPL to increase TG clearance and activate PPAR-alpha to induce HDL synthesis
  • Uses - Reduce TG 20%-50% HDL 10-30% , LDL  5-20 %
  • Most effective for high triglycerides

Adverse Effects

  • Dyspepsia Gallstones Myopathy–When used in combination with HMG CoA reductase inhibitors it may increase severe side effects of these drugs- enhanced risk of rhabdomyolysis.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Method of excretion of each Lipid lowering drug?

A

Niacin- renal

Fibrates- renal/urine

Statins- liver

Bile resins- feces

Ezetimibe- liver and kidney

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Most effective at decreasing TAGs?

Decreasing LDL?

INcreasing HDL?

A

Tags- Fibrates

LDL- statins

HDL- niacin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Statin with Bile

Benefits?

Downfall?

A

mevacor with cholestyramine.

Benefit-

  • A good combination as both have different mechanisms of action with Statins targeting cholesterol synthesis and the bile acid resins targeting dietary cholesterol absorption.
  • Likewise, there is little overlap in side effects.

Downfall-

  • There are issues with timing. You must take the statin 1 to 2 hr before the cholestyramine or three hrs after to avoid problems with statin drug absorption caused by cholestyramine.
  • As with cholestyramine alone there are compliance issues. (remember resins decrease absorption of fat soluble vitamins and some drugs and taste gross)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Statin with Eztimibe- trade name?

Benefits?

Downfall?

A

TradenameVytorin.

benefits

  • Vytorin is available as single pill containing both drugs
  • he effect of the two drugs is additive.
  • There are minimal side effects with Zetia and there is little evidence that combining zetia with statins exacerbates the side effects of the statins. Rather, the combination may be used to reduce potential side effects of the statins by allowing for a lower dose of the statin drug to be used to obtain a specific reduction in cholesterol.

Downfall

  • combination of simvastatin and ezetimibe (Vytorin) was no more effective than simvastatin alone. While the combination reduced cholesterol better than simvastatin alone, there was no significant improvement in intima media thickness (IMT) of carotid artery measured using ultra sound imaging patients heterozygous familial hypercholesterolemia;
  • Other studies found postiive effects of Vytorin.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Statin with Fibrates?

Benefits?

Downfall?

A

Gemfibrozil (fibrate) has been used with the statin drugs as a way to enhance the lowering of triglycerides. Unfortunately, both drugs cause myopathy and the combination may enhance the chances myopathic side effects including rhabdomyolysis. The combination is still in use but must be monitored closely

17
Q

Statins and Niacins

A

Benefit very unclear

  • This combination runs the risk of increased serum tranaminase and increased myosistis and even rhabdomyolysis.
  • ONe study found that Niacin increased HDL reduced triglycerides and decreased mean carotid intima-media thickness at both 8-14 months.The above Data seem to Favor Niacin over Ezetimibe as a combination
  • but the AIM HIGH study has changed this thinking. AIM-HIGH found that while niacin improved the lipid profile it did not meet the endpoint of the study, which was the “first event of the composite of death from coronary heart disease, nonfatal myocardial infarction, ischemic stroke, hospitalization for an acute coronary syndrome, or symptom-driven coronary or cerebral revascularization.”
18
Q

Causes of secondary dylipiedmia? (5)

A
  1. Diabetes
  2. Hypothyroidism
  3. Obstructive liver disease
  4. Chronic renal failure
  5. Drugs that increase LDL cholesterol and decrease HDL cholesterol o (progestins, anabolic steroids, and corticosteroids).

Secondary causes must be excluded or, if appropriate, treated, before initiating treatment

19
Q

New recommendations for choelsterol focus on what? What did the old recommendations focus on?

How do you treat

  1. CV disease patietn under 70
  2. Patient with LDL over 190
  3. Diabetic between 40-75
  4. none of the above conditions but 10 year risk

What is moderate intensity tx? What is high?

A

The recommendations focus more on the evidence for reduction in mortality rather than cholesterol level. These move treatment away from specific targets for LDL.

  1. For patients CV disease: For Adults less under 70 190: High intensity statin or moderate intensity if not a candidate for high intensity statin treatment
  2. For those with a LDL >/= 190: High intensity statin or moderate intensity if not a candidate for high intensity statin treatment
  3. Diabetes (type 1 or type 2) Age 40-75 years Moderate intensity Statin- High Intensity Statin if 10-year risk is greater than 7.5%
  4. None of the above conditions but 10-year risk is greater than 7.5% Moderate to high intensity statin

Definitions:

  • High intensity treatment with a statin = Lowering of LDL-C by >/= 50% or better
  • Moderate intensity treatment with a statin = Lowering LDL-C by 30-50%
20
Q

Progression of LDL lowering Drug therapy

A
  1. LDL lowering Drug therapy- Start STATIN or Bile acid sequestrant or nicotinic Acid (6 weeks)
  2. If goal not met increase dosage of Staint or Add bile acid or nicotinic acid (6 weeks)
  3. If goal not met intentisfy drugs or refer to lipid specialist
  4. monitor adherence and response to therapy (eery 4-6 months)
21
Q

Major risk factors (excluding LDL) that modify LDL goals

What do these modifications mean in terms of LDL nnumbers?

A

Table 3. Major Risk Factors (Exclusive of LDL Cholesterol) That Modify LDL Goals *

  1. Cigarette smoking
  2. Hypertension (blood pressure ≥140/90 mmHg or on antihypertensive medication)
  3. Low HDL cholesterol (≤40 mg/dL)†
  4. Family history of premature CHD (CHD in male first-degree relative ,55 years; CHD in female firstdegree relative ,65 years)– diabetes is considered a CHD disease.
  5. Age (men ≥45 years; women ≥55 years)

Risk Category LDL Goal (mg/dL)

CHD and CHD risk equivalents <100

Multiple (2+) risk factors* <130

0-1 risk factor <160

22
Q

MOA of PCSK9 inhibitors. List them

MOA

Side effects

What disease has a mutation in PCSK9 and what happens?

A

Alirocumab (praluent) and Evolocumab (repatha)

INteract with the LDL receptor on the liver and controls plasma cholesterol by regulating the # of LDL receptors.

When activated, PCSK9 binds to LDL receptors and targets the LDLD teceptor to the lyosome where it is destroyed.

When PCSK9 is inactive, the LDL receptors is recylced leading to lwoer plasma LDL. MOA- monoclonal Antibodies that bind to PCSK9 prevent it rfrom targetting the LDL recpetors for descrution removing more LDL from the serum

Side effects- injection site swelling, severe allergic reaction, possible neurocognitive effects and very expensive

PCSK9 has a “gain of function” mutations in ppl with inherited heterozygous familial hypercholesterolemia